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The NCI-MATCH was designed to characterize the efﬁcacy of targeted therapies in histology-agnostic driver mutation-positive
malignancies. Sub-protocols F and G were developed to evaluate the role of crizotinib in rare tumors that harbored either ALK or
ROS1 rearrangements. Patients with malignancies that progressed following at least one prior systemic therapy were accrued to the
NCI-MATCH for molecular proﬁling, and those with actionable ALK or ROS1 rearrangements were offered participation in subprotocols F or G, respectively. There were ﬁve patients who enrolled on Arm F (ALK) and four patients on Arm G (ROS1). Few grade 3
or 4 toxicities were noted, including liver test abnormalities, and acute kidney injury. For sub-protocol F (ALK), the response rate was
50% (90% CI 9.8–90.2%) with one complete response among the 4 eligible patients. The median PFS was 3.8 months, and median
OS was 4.3 months. For sub-protocol G (ROS1) the response rate was 25% (90% CI 1.3–75.1%). The median PFS was 4.3 months, and
median OS 6.2 months. Data from 3 commercial vendors showed that the prevalence of ALK and ROS1 rearrangements in
histologies other than non-small cell lung cancer and lymphoma was rare (0.1% and 0.4% respectively). We observed responses to
crizotinib which met the primary endpoint for ALK fusions, albeit in a small number of patients. Despite the limited accrual, some of
the patients with these oncogenic fusions can respond to crizotinib which may have a therapeutic role in this setting.
npj Precision Oncology (2022)6:13 ; https://doi.org/10.1038/s41698-022-00256-w

INTRODUCTION
The NCI MATCH trial is an expansive National Clinical Trials
Network/NCI Community Oncology Research Program effort,
developed and implemented with the goal of providing a largescale platform for the study of targeted agents in molecularly
deﬁned malignancies. With the availability of molecular testing
and drugs designed to target actionable mutations, this effort has
been one of the largest to provide access to treatment based on
driver mutation status, rather than histology or primary site of
disease. The chimeric proteins that result from gene fusions
involving ALK or ROS1 are both therapeutic targets of the tyrosine
kinase inhibitor crizotinib. The kinase domains of ALK and
ROS1 share signiﬁcant amino homology within the ATP-binding
sites, resulting in high-afﬁnity binding of crizotinib in cell-based
assays. The role that ALK plays in normal physiology is poorly
understood. In the wild-type state, activation of the ALK protein is
thought to be potentially mediated by ligand-induced dimerization. Oncogenic activation of ALK arises from a rearranged protein
in which the intact tyrosine kinase domain of ALK is fused to a
variety of upstream partners resulting in constitutive activation of
the ALK tyrosine kinase. This, in turn, results in activation of
downstream signaling involving the MAPK, PI3K, and JAK/STAT

pathways, thereby promoting increased cell growth and
proliferation1.
In non-small cell lung cancer (NSCLC) EML4-ALK is one of the
more common fusion events, but there are other reported variants
of ALK fusion proteins that do not involve the EML4 gene such as
KIF5B-ALK, STRN-ALK, HIP1-ALK, VCL-ALK, NPM-ALK, and TGF-ALK2–5.
ALK fusions have been identiﬁed as drivers of oncogenesis in a
variety of other malignancies6. ALK-positive anaplastic large cell
lymphomas (ALCLs) represent a distinct subset of lymphomas that
are associated with better outcomes in comparison to ALKnegative ALCLs. Up to 50% of ALK-positive ALCLs harbor ALK
fusions, the most common of which is the t(2;5)(p23;q35)
translocation, resulting in the formation of NPM-ALK. In solid
tumors, ALK rearrangements including TPM4-ALK and TPM3-ALK
have been identiﬁed in up to 50-75% of inﬂammatory myoﬁbroblastic tumors (IMT). These fusions are transforming in various cell
lines and animal models. Recently, ALK rearrangements have been
found in spitzoid neoplasms, a group of melanocytic tumors
including Spitz nevi, spitzoid melanomas, and atypical Spitz
tumors7.
ROS1 encodes a transmembrane protein with an extracellular
domain that is partially analogous to ﬁbronectin8. Although the
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function of wild-type ROS1 is poorly understood, it is speculated that
ROS1 might translate adhesion events to intracellular signaling
because of the structural similarities to cell adhesion molecules. In
NSCLC, the most common ROS1 fusion partner is CD74. Less common
partners include SDC4, EZR, SLC34A2, TPM3, LIMA1, and MSN. The ROS1
proto-oncogene has been identiﬁed to be translocated in NSCLC with
a frequency of 1.7% (18/107) to 2.6% (17/656)9,10. While rare, ROS1
rearrangements have also been reported in gastric cancers,
glioblastomas, cholangiocarcinomas, ovarian cancers, colorectal
cancers, inﬂammatory myoﬁbroblastic tumors, angiosarcomas, and
epithelial hemangioendotheliomas8,11,12.
Crizotinib is a ﬁrst-in-class ATP-competitive small-molecule
inhibitor of ALK, ROS1, and Met/hepatocyte growth factor receptor
(HGFR). Crizotinib demonstrated concentration dependent inhibition of ALK kinase activity in biochemical and cell-based assays. In
addition, crizotinib demonstrated growth inhibition and increased
apoptosis of tumor cell lines with ALK fusion variants (EML4-ALK or
NPM-ALK). Mice xenografts with ALK fusion variants also
responded to crizotinib treatment in a dose dependent fashion.
Based on its signiﬁcant activity, crizotinib received FDA approval
for ALK-positive NSCLC in 2011, for ROS1-positive NSCLC in 2016,
and ALK-positive ALCL in 2021. In prior studies, common toxicities
related to crizotinib included reversible visual disturbances,
gastrointestinal side effects, fatigue, transaminitis and edema.
The NCI-MATCH subprotocols F and G were designed to study
the activity of crizotinib in tumors other than NSCLC or ALCL with
ALK and ROS1 rearrangements, respectively. Given the common
therapeutic option in these subprotocols, the results of both
studies were combined for this report.
RESULTS
Patient characteristics
A total of 5 patients enrolled on sub-protocol F (ALK), with the ﬁrst
patient enrolled on November 24, 2015, and the last on April 24,
2019. One patient was ineligible since treatment was started
before a 28-day washout following prior treatment, resulting in
four analyzable patients (Supplemental Fig. 1). A total of 4 patients
enrolled on sub-protocol G (ROS1), with the ﬁrst patient enrolled
on July 7, 2016, and the last on September 13, 2018 (Supplemental
Fig. 2). Due to poor accrual, both sub-protocols were closed.
Among both sub-protocols, most patients had gastrointestinal
malignancies (Table 1). All but one patient had received two or
more prior lines of therapy. Previously reported EML4 and GOPC
fusion partners were most frequently identiﬁed for ALK and ROS1,
respectively. A median of four cycles of crizotinib were
administered in both sub-protocols.
Response assessment and survival outcomes
For sub-protocol F (ALK), the response rate was 50% (90% CI
9.8–90.2%; Fig. 1) with one, ongoing complete response; the
median PFS was 3.8 months, and the 6-month PFS rate was 25%
(90% CI 6.0%-100%; Fig. 2). Despite the very low accrual, the null
hypothesis of response rate not exceeding 5% can be rejected at
the 1-sided .014 signiﬁcance level, meeting the primary endpoint.
The median overall survival was 4.8 months (Fig. 2; Supplemental
Table 3). For sub-protocol G (ROS1), with a 25% responses rate
(90% CI 1.3–75.1%; Fig. 1), the p-value for testing the null of 5%
was 0.186. The median PFS was 4.3 months, and the 6-month PFS
rate was 50% (90% CI 22–100 %; Fig. 2). The median overall
survival was 6.2 months (Fig. 2; Supplemental Table 3).
Adverse events
There were very few grade 3 or 4 toxicities at least possibly related
to treatment; these included liver test abnormalities, abdominal
pain, and acute kidney injury. Less severe edema,
npj Precision Oncology (2022) 13

Table 1.

Patient Characteristics.
ALK fusion
(n = 4)

ROS1 fusion
(n = 4)

Female

3 (75%)

2 (50%)

Age: median (range)

59 (52–69) years

54 (47–76) years

Race: White

4 (100%)

4 (100%)

Performance Status 0

3 (75%)

2 (50%)

1 (25%)

2 (50%)

1
Number of Prior Therapies: 1

1 (25%)

0 (0%)

2
3

2 (50%)
0 (0%)

1 (25%)
1 (25%)

>3

1 (25%)

2 (50%)

Weight loss previous 6 months: 4 (100%)
< 5%

4 (100%)

Histologies
Cholangiocarcinoma

1

Pancreatic adenocarcinoma
Colorectal adenocarcinoma

1
2

Ovarian adenocarcinoma

1

Carcinoma of unknown
primary

1

Leiomyosarcoma
Fusion partners

1

EML4

3

ACTG2

1

STRN

1

GOPC

1

4

hypoalbuminemia, and liver test abnormalities were also observed
(Supplemental Table 4). There were two deaths on sub-protocol F
attributed to disease progression or a cause that was not
otherwise speciﬁed. There was one death on sub-protocol G
attributed to disease progression.
Expanded molecular cohort
In an expanded molecular cohort of subjects compiled by three
commercial vendors, the detection of ALK or ROS1 rearrangements
outside of NSCLC or lymphoma was rare (Supplemental Table 5). A
review of over 30,000 tumors excluding those with NSCLC or
lymphoma from two of these commercial vendors identiﬁed ALK
rearrangements in 1/1,000 specimens and ROS1 rearrangements
in 4/10,000 specimens. One external dataset included clinical
characteristics of these cases. Whereas there was a similar
proportion of females (n = 18, 49%) and males (n = 19, 51%) with
ALK rearrangements, there were more females (n = 10, 63%) than
males (n = 6, 37%) with ROS1 rearrangements. Although there
were similar median ages for patients with either rearrangement,
there were younger patients with ALK rearrangements than ROS1
rearrangements (ALK median 57 years, range 25–83; ROS1 median
60.5 years, range 41–89). ALK rearrangements were most
frequently seen in thyroid, colorectal, and soft tissue tumors in
this cohort (Supplemental Table 6). ROS1 rearrangements were
most frequently seen in glioblastoma multiforme and breast
cancer (Supplemental Table 7). The most frequent ALK fusion
partners were EML4 (38%) and STRN (16%) and the most frequent
ROS1 fusion partner was GOPC (44%) (Fig. 3). Of the evaluable
tumors, almost all with ALK or ROS1 fusions had low or
intermediate TMB (96%; Supplemental Table 8) and were MSI
stable (98%; Supplemental Table 9).
Published in partnership with The Hormel Institute, University of Minnesota
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Fig. 1 Waterfall and Swimmer plot of responses and their
durations. The waterfall plot shows responses for all patients who
had response assessment (A n = 7). One patient on subprotocol G
(ROS1) is not included as treatment was discontinued during cycle
one for toxicity and response was not evaluable. The Swimmer plot
shows the duration of responses for all patients (B n = 8). CR
complete responses, PD progressive disease, PR partial response.

DISCUSSION
Accrual to sub-protocols F and G was limited, reducing our ability
to assess the efﬁcacy of treatment with any precision. However,
we can conclude that the true response rate for sub-protocol F
exceeds the null hypothesis rate of 5%, at the 1-sided .014 signiﬁcance level. We observed responses to crizotinib in patients
whose tumors harbored ALK or ROS1 rearrangements outside of
the FDA-approved indications for this therapy. However, the
median overall survivals of 4.8 and 6.2 months suggest that the
anti-tumor activity we observed was modest. Many of the
reported toxicities were similar to those reported in prior trials
with crizotinib. Furthermore, our rates of detection and analysis of
external datasets from three commercial vendors suggest that ALK
and ROS1 rearrangements are very rare outside of NSCLC.
Globally, there have been additional efforts to target either ALK
or ROS1 in rare tumor types. Some of the more successful
attempts have been in the pediatric population. For instance,
response rates as high as 80–90% with ALK inhibitor therapy have
been observed in the treatment of anaplastic large cell
lymphomas which harbor ALK translocations13,14. Inﬂammatory
myoﬁbroblastic tumors are another rare malignancy that frequently harbor ALK or ROS1 translocations15–17. In one case, the
ALK rearrangement resulted from a complex pattern of chromosomal rearrangements called chromoplexy, and that patient had
durable beneﬁt from treatment with the ALK inhibitor ceritinib18.
Finally, molecular events involving ALK have also been identiﬁed
in aggressive thyroid cancers and neuroblastomas19,20. While the
role of ALK and ROS1 inhibitors is now established as standard of
Published in partnership with The Hormel Institute, University of Minnesota

Fig. 2 Progression-free and overall survival for both subprotocols. The PFS A and OS B are presented for both ALK
(EAY131-F) and ROS1 (EAY131-G) sub-protocols.

care among ALK - or ROS1 -positive NSCLC in addition to some of
the rare tumors listed above, our data suggest that patients with
other tumor types that harbor these mutations may also beneﬁt
from targeted therapy. The authors are not aware of other plans to
develop crizotinib further for these indications.
There are several potential explanations for the modest impact
on response rate and survival noted in both sub-protocols. First,
this was a pre-treated population with most patients having
received at least 2 lines of prior therapy. As a result, it is likely that
these patients had more resistant tumors at the time of treatment.
Somatic mutations that confer resistance to crizotinib are now
well characterized among series of patients with NSCLC and
acquired resistance mutations in ALK include L1196M, G1202R,
and S1206Y21. Alternatively, these patients’ tumors may have
developed bypass pathway signaling or had concurrent mutations
as a result of prior therapy which limited the activity of crizotinib.
One patient had a concurrent BRAF fusion, which may have been
the actual oncogenic driver. Since the approval of crizotinib, more
potent ALK and ROS1 inhibitors have received FDA approval such
as alectinib22, brigatinib23, entrectinib24, and lorlatinib25,26. Enrollment to basket trials with some of these agents may have
competed with enrollment to NCI-MATCH. At this time, it is not
known if one of these newer agents would yield improved efﬁcacy
in these other tumor types with ALK or ROS1 fusions. Finally, it has
been suggested that sequencing RNA might be more appropriate
than DNA for the detection of fusions given the difﬁculties of
covering all of the introns from which rearrangements can arise27.
The central NCI-MATCH NGS assay did sequence fusions from RNA
input, but the assay was speciﬁcally targeted for known fusions.
The external laboratories use a variety of platforms but many scan
introns in DNA. For that reason, there may have been some cases
with novel ALK or ROS1 fusions that were not detected for
inclusion in NCI-MATCH.
npj Precision Oncology (2022) 13
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Fig. 3 Fusion partners for ALK and ROS1 in the expanded molecular cohort. The most common fusion partners are shown for ALK and ROS1
from the expanded molecular cohort.

Our analysis of the expanded molecular cohort identiﬁed ALK or
ROS1 rearrangements in many types of solid tumors. The
frequencies of fusion partners did not necessarily match those
reported for non-squamous NSCLC but included many of the
known fusion partners. Almost all the tumors in the expanded
cohort with ALK or ROS1 rearrangements had low or intermediate
TMB and were microsatellite-stable, suggesting that there are few
other molecular drivers in these cases.
The NCI-MATCH is ongoing with open sub-protocols. Recently,
the experience performing molecular proﬁling on almost 6,000
patients for NCI-MATCH was reported28. Thirty subprotocols were
open at some point during this screening period and eleven of
them met their accrual goals of 31 eligible patients. None of the
subprotocols that targeted an alteration with a prevalence <1.5%
met its accrual goal during this centralized screening phase. These
results highlight the difﬁculties of identifying eligible patients with
rare molecular events for clinical trial participation despite the
widespread activation of NCI-MATCH and signiﬁcant engagement
with community oncologists. It is possible that just-in-time clinical
trial activation mechanisms could have expanded the number of
potential sites with eligible patients and improved accrual to
subprotocols with rare molecular events. There was a higher rate
of molecular alterations and co-occurring mutations in NCIMATCH than seen in TCGA29, which may have resulted from
patient selection strategies and larger sample size for some tumor
types like cholangiocarcinoma in NCI-MATCH. Many of the cooccurring mutations were in tumor-suppressor genes that have
been implicated in therapeutic resistance to targeted therapies.
Given the genomic complexity of many cancers and the resistance
that invariably develops with most single agent targeted
therapies, the NCI-ComboMATCH (EAY191)30 will test combinations of targeted therapies that are supported by robust in vivo
evidence.
In spite of the low incidence of ALK and ROS1 rearrangements
among adults with solid tumors other than NSCLC, we feel it is still
critical to pursue comprehensive molecular testing for rare tumors
and those with limited treatment options. Ongoing evaluation of
newer inhibitors is needed in the rare event of an ALK or ROS1
translocation. Given rarity of these events in adult solid tumors, it
will require collaboration amongst the larger oncology community
to study the efﬁcacy of these agents in this setting.

standard systemic therapy or for whom no standard therapy exists were
registered on the screening step of the NCI-MATCH protocol to undergo
molecular proﬁling analysis on fresh tumor biopsies. The latter proﬁling
was performed in speciﬁc Clinical Laboratory Improvement Amendments
(CLIA)-accredited laboratories and consisted of next generation sequencing (NGS) with an investigational targeted gene panel, the Oncomine
Ampliseq assay31. This assay was validated to detect speciﬁc targeted gene
fusions with 97.67% sensitivity and 99.99% speciﬁcity. In the second phase
of the trial, 30 academic and commercial laboratories that perform NGS
testing were reviewed and evaluated for concordance of test results with
the central NCI-MATCH laboratory assay. These laboratories were then
asked to refer patients with an actionable mutation for enrollment. Patients
whose tumors were found to harbor actionable ALK or ROS1 rearrangements (Supplementary Tables 1-2) were offered participation in subprotocols F or G, respectively. The protocol allowed for subsequent
treatment on other subprotocols if relevant molecular proﬁles were
present and eligibility criteria were met. The study was initiated after
approval from the Central Institutional Review board and was conducted in
accordance with the Declaration of Helsinki. Written informed consent was
obtained from all patients.
Patients with NSCLC were excluded from both sub-protocols, given that
the FDA previously approved crizotinib for patients with NSCLC harboring
ALK or ROS1 rearrangements. Patients who had already received ALK or
ROS1 inhibitors were also excluded. Patients were treated with crizotinib
250 mg twice daily on 28-day cycles. Dose reductions to 200 mg twice daily
or 250 mg daily were allowed for treatment-related adverse events.
Responses were assessed using revised RECIST (Response Evaluation
Criteria in Solid Tumors) version 1.132, Cheson criteria for patients with
lymphoma,33 and RANO criteria for patients with glioblastoma
multiforme30.

Statistical considerations
The primary objective of these NCI-MATCH sub-protocols was to evaluate
the proportion of patients who had objective response, deﬁned as
complete or partial response, to a targeted study agent. This proportion,
termed the objective response rate and expressed as a percentage, was
compared against a null benchmark value of 5%. If the observed objective
response rates were ≥ 5/31 (16%), it would then be concluded that the
agent is promising and worthy of further investigation. Allowing for a 10%
ineligibility rate, 35 patients were to be accrued to each sub-protocol, to
obtain 31 eligible patients per sub-protocol. With this design, the power
was 91.8% to conclude an agent is promising if its true response rate is
25%, and the type 1 error (one-sided) was 1.8% of its true response rate is
5%. Secondary objectives included the proportion of patients who were
progression-free at 6 months (PFS6), progression-free survival, and toxicity
assessment.

METHODS
Study design and eligibility

Expanded molecular cohort

The NCI-MATCH trial is an ongoing, nationwide clinical trial with integrated
multiple independent single-arm sub-protocols, each addressing an
actionable molecular alteration. Each sub-protocol aims to evaluate a
single agent or combination treatment for which at least a recommended
phase 2 dose has been determined.
Patients with histologically documented solid tumors, lymphomas, or
myelomas whose disease had progressed following at least one line of

Three NGS vendors provided data on the detection of ALK and ROS1
rearrangements in the tumors of patients excluding NSCLC and lymphoma
as part of their commercial testing services in an effort separate from NCIMATCH. We used these data to see how the frequency of ALK and ROS1
rearrangements in this expanded molecular cohort compared to that
detected by NCI-MATCH. Two of these vendors provided the total number
of cases tested, and one vendor provided additional data on the clinical
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characteristics of these tumors, microsatellite instability (MSI) status, and
tumor mutation burden (TMB). These cases were not necessarily included
in NCI-MATCH. MSI was examined using over 7,000 target microsatellite
loci and compared with the reference genome hg19 from the University of
California, Santa Cruz (UCSC) Genome Browser database. The status was
deﬁned as MSI-high (MSI-H) or MSI-low/microsatellite stable (MSS). The
number of microsatellite loci that were altered by somatic insertion or
deletion were counted for each sample. Only insertions or deletions that
increased or decreased the number of repeats were considered. Genomic
variants in the microsatellite loci were detected using the same depth and
frequency criteria used for mutation detection. MSI-NGS results were
compared with results from over 2,000 matching clinical cases analyzed
with traditional PCR-based methods. The threshold to determine MSI by
NGS was determined to generate a sensitivity of >95% and speciﬁcity of
>90%. TMB was measured by counting all nonsynonymous missense
mutations found per tumor that had not been described previously as
germline alterations [592 genes and 1.4 megabases (MB) sequenced/
tumor]. Potential germline mutations were excluded by comparing data
against dbSNP 137 full and 1000 Genomes Phase 3. The threshold to
deﬁne TMB-high (TMB-H) was ≥17 mutations/MB and was established by
comparing TMB with MSI by fragment analysis in colorectal cancer cases,
based on reports of TMB having high concordance with MSI-H in colorectal
cancer. TMB-intermediate was deﬁned as ≥ 7 but <17 mutations/
megabase, and TMB-low was deﬁned as ≤6 mutations/megabase. These
data were summarized and the donut charts were created with R Studio
(version 1.2.5033) and tidyverse packages.

Reporting summary
Further information on research design is available in the Nature Research
Reporting Summary linked to this article.

DATA AVAILABILITY
The data generated or analysed from these clinical trials are included in this
published article. The expanded molecular datasets generated or analysed for the
current study are available from the corresponding author on reasonable request.
The deidentiﬁed sequencing data from Caris Life Sciences are owned by Caris Life
Sciences. Qualiﬁed researchers can apply for access to these summarized data by
contacting Joanne Xiu, PhD and signing a data usage agreement. Strata Oncology
will provide de-identiﬁed molecular results upon request for Strata-referred samples
included in this analysis. More speciﬁcally, they will provide all prioritized variants for
the ALK/ROS1 + patients, including for the fusions 5′/3′ partners, junctions and read
support, as well as cancer type, age range, etc. Requests should be addresses to Dan
Hovelson, PhD. Tempus has provided summary statistics, including the number of
screened patients for this cohort and the count of the speciﬁc positives for postpublication replication and veriﬁcation purposes (Supplemental Table 10). The
protocols are available as supplementary materials.
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